UC Investment Office, an existing Constellation backer, has returned to contribute to a $100m round that took its total equity funding to $229m.
US-based cancer-focused biopharmaceutical company Constellation Pharmaceuticals raised $100m today in a funding round backed by University of California Investment Office.
SR One, the corporate venturing arm of healthcare group GlaxoSmithKline, also participated in the round, as did financial services conglomerate Fidelity Management and Research, Cormorant Asset Management, Deerfield Management, Hillhouse Capital, NS Investment, OrbiMed and Sirona Capital.
Venrock Healthcare Partners, Column Group, Third Rock Ventures, Topspin Partners and Casdin Capital filled out the investors.
Founded in 2008, Constellation is working on immuno-oncology therapies that rely on epigenetics, the field of genetics that focuses on understanding gene mutations that are not linked to the DNA.
The funding will go towards the further development of the company’s lead candidates: CPI-1205 and CPI-0610. Constellation will also advance a second-generation program into the clinic and seek to identify additional candidates.
CPI-1205 is currently undergoing trials in metastatic castration-resistant prostate cancer, and in immunotherapies in…
